A wild type appendix cancer result means the test did not detect a mutation in the genes it was set up to examine. It does not mean your tumor has no mutations, and it does not mean the drugs built for wild type colon cancer will work for you.

My husband David had his appendix and right colon removed in February 2024. The pathology came back as poorly differentiated goblet cell adenocarcinoma, 6.5 centimeters, growing through the wall into the lining of his abdomen, with cancer in one of twenty-one lymph nodes and two separate tumor deposits. Not an incidental finding. Not a small problem.

Dr. JP Shen ordered genomic profiling on the tumor. Six weeks later the report came back with zero actionable targets, and a line stating that no approved or investigational drug was indicated for anything found in his sample.

In patient conversations, a result like that often gets shortened to wild type. That phrase hides quite a lot.

His report also listed thirty-nine alterations. Every one of them was classified a variant of unknown significance, meaning the lab found them and cannot yet say what they do. None of the genes that usually drive appendix cancer were on the list. No KRAS. No GNAS. No TP53. His tumor mutation burden came back at 1 mutation per megabase, which is about as low as that number goes. His tumor was microsatellite stable, and the mismatch repair proteins on his surgical pathology were all intact.

So David is wild type for the genes everyone talks about, and he does not have a mutation-free tumor. Both are true at the same time. The words on his report only carry one of them.

The words on a molecular pathology report are not written for patients. They are written for oncologists, and they carry a hundred years of lab shorthand that nobody stops to explain. “Wild type” is the worst offender. It sounds like a verdict. People read it and hear either “you’re clean” or “there’s nothing to target,” and both readings can be wrong.

The term comes from early genetics research, long before cancer sequencing existed. Scientists breeding fruit flies needed a word for the ordinary version of a gene, the one you’d find in a fly caught in the wild, as opposed to the altered version they created in the lab. Wild type meant normal. Unchanged. That is still all it means today.

So when your report says KRAS wild type, it is saying one thing: the lab looked at KRAS and did not find a mutation. It is not making a statement about your tumor, your outlook, or your treatment options. It is reporting on one gene.

What a wild type appendix cancer result actually depends on

Many molecular tests used in cancer care are panels. A panel is a defined list of genes or genomic regions the lab is set up to examine. Some panels cover 20 genes. Some cover 500. The report tells you about what was on that list. Genes outside the panel may not have been examined at all, so an unreported gene should not be assumed to be normal.

This matters for appendix cancer, because appendiceal tumors are often tested with panels, and interpreted through frameworks, that were developed largely around more common gastrointestinal cancers, including colorectal cancer. Those panels look hardest at the genes that drive colon tumors. Appendiceal tumors, especially goblet cell tumors, are not colon tumors.

Two sequencing studies show what that mismatch does. In the first, researchers ran a 32-gene colorectal panel on 25 appendiceal cancers. The colorectal-type appendiceal adenocarcinomas lit up the way colon tumors do, with TP53 mutations in 5 of 7 cases and KRAS in 3 of 7. The goblet cell tumors did almost nothing. Only 4 of 11 carried any mutation the panel was looking for. No KRAS or NRAS mutations showed up at all. On paper, most of those patients were wild type.

Then the same team ran a much larger 409-gene panel on a few of those goblet cell cases, and mutations appeared. They were in Wnt signaling genes, USP9X, NOTCH1, CTNNA1, CTNNB1 and TRRAP, genes that were not included in the smaller colorectal-focused panel used in that study.

A second team sequenced 34 goblet cell tumors on a 282-gene panel. The genes that came up most often were ARID1A, ARID2, CDH1, RHPN2 and MLL2. KRAS turned up in only 2 of the 34. The authors concluded that these tumors have a distinct mutational profile from both typical appendiceal carcinoids and colorectal adenocarcinomas.

I don’t want to oversell this. The honest version is not “just order a bigger panel and they’ll find something.” Even on that 282-gene panel, the average tumor carried about three mutations and some carried none at all. A bigger panel is a better look, not a guarantee. But a goblet cell patient tested on a colon panel is being measured against the wrong reference, and the word that comes back is wild type.

David is the proof of that limit. He did not get a small panel. His test was Altera, which sequences the whole exome of the tumor and the whole exome of the patient’s normal tissue side by side, then adds RNA sequencing on top. That comparison is what lets a lab separate a cancer mutation from something a person was simply born with, and it is close to the largest look currently available. No KRAS, no GNAS, no TP53 turned up anyway, and thirty-nine alterations came back that nobody can interpret yet. A bigger test did not convert his result into an answer. It converted it into a longer list of open questions, which is a different thing and worth expecting.

Which subtypes come back wild type most often

This is the question most people actually want answered, and it has a partial answer.

Goblet cell adenocarcinoma stands out as an appendiceal subtype with unusually low rates of the common KRAS and GNAS drivers, a pattern reported across multiple studies. A 703-case series run on a 315-gene test found KRAS in 13 percent of goblet cell tumors and GNAS in 6 percent, against 77 percent and 52 percent in mucinous adenocarcinoma. A Japanese national database of 314 advanced cases found KRAS in 7.7 percent and GNAS in 5.1 percent. A Memorial Sloan Kettering study found that 59 percent of metastatic goblet cell tumors carried none of the three genes that define the other subtypes, compared with 11 percent of mucinous and 11 percent of colonic-type tumors. The two goblet cell sequencing studies described above found the same pattern on smaller numbers.

If you have goblet cell disease and the usual appendix cancer drivers come back wild type, that result is not unusual for this subtype. It is not a sign that the lab did a bad job or that your case is strange.

The Memorial Sloan Kettering authors add a caution worth carrying with that finding. Tumors in the group they called triple negative have few recurrent mutations and may be driven by copy number changes, meaning whole stretches of DNA gained or lost rather than the single-letter changes a report usually lists. Nothing found is not the same as nothing there.

Signet ring cell tumors appear to behave similarly, though the studies are much smaller and disagree with each other, so I would treat that as a hint rather than a finding.

Low-grade mucinous tumors and pseudomyxoma peritonei sit at the opposite end. Across the studies that microdissected the tissue or went back for better material, roughly 90 percent or more carried KRAS, GNAS, or both. Studies that sequenced bulk peritoneal tissue without that step reported figures closer to 40 percent, which is a large part of why the published numbers disagree. A wild type result in this group raises an important question about whether low tumor cellularity or the tissue selected for testing contributed to the negative result, which is the next section.

Non-mucinous appendiceal adenocarcinoma looks the most like colorectal cancer, with much higher rates of APC and TP53 than the mucinous subtypes.

What nobody has published is a straight comparison of how often each subtype comes back with nothing at all. Reported rates of “no alteration detected” range from zero to 43 percent across studies, and that spread mostly reflects how many genes were tested and how the tissue was handled, not which cancer the patient had. So the honest version is that the field can name which subtypes are least likely to show the usual drivers, and cannot yet say which subtype has the highest true wild type rate.

A wild type appendix cancer result can also be a sampling problem

There’s a second reason a report can read wild type when the tumor isn’t, and it has nothing to do with the gene list. It has to do with what went into the tube.

Mucinous appendix tumors and pseudomyxoma peritonei produce enormous amounts of mucus with very few cancer cells suspended in it. If the lab sequences a peritoneal mucin sample, much of what it reads is mucus and normal tissue. If there are too few tumor cells in the sample, mutations can be diluted below what the test can detect.

A 2026 study put a number on this. Researchers analyzed tumor samples from 167 patients with confirmed pseudomyxoma peritonei. When testing of the peritoneal disease did not identify mutations, the researchers used additional tumor material and more sensitive approaches, including tissue from the primary tumor when it was available. KRAS mutations turned up in 89 percent of cases and GNAS in 83 percent. Some cancer-related mutation was found in 98 percent of the samples they analyzed. In 48 percent of cases, the mutational diagnosis was based on the primary tumor sample.

If those researchers had stopped at the first peritoneal sample, a large group of patients would be walking around with a wild type report describing a tumor that carries two of the best known drivers in this disease.

Ask your team which sample the lab used, and how much of it was actually tumor. Good molecular reports state the tumor cellularity, sometimes called percent tumor nuclei. If that number is low, a negative result deserves a second look rather than a shrug.

The labs say this themselves, in the fine print nobody reads. David’s report states that samples with less than 20 percent tumor content may have reduced sensitivity and produce false negative results, that his assay could not see anything present below 5 percent of the sample, and then this: the lack of a variant call does not necessarily indicate the absence of a variant, because technical limits mean some regions cannot be read. That sentence is printed on his own report, under the headline that said zero targets. It is the most important line on the page and it is in six-point type at the back.

His report has one gap, and it is the same gap I am telling you to ask about. Nowhere does it say how much of his sample was actually tumor. The lab states plainly that samples with less than 20 percent tumor content can give false negative results. It also states that tumor purity is not taken into account when it reports its numbers. So the report names the thing that matters and then does not give it. That question is now on my list for the lab.

The assay did find alterations in David’s tumor at levels as low as 7 percent of the DNA it read, which gives me some reassurance that it was capable of picking up low-level findings in that specimen. But those percentages are not the same thing as the share of tumor cells carrying a change, and without the tumor purity number I cannot tell from the report alone whether every negative on it is truly negative. I would rather have that number in writing than infer my way to it.

Wild type does not mean the colon cancer drugs will work

This is the assumption I see most often, and it comes from a real place. In metastatic colorectal cancer, RAS wild type is a genuine gateway. It’s the result that makes a patient eligible for the anti-EGFR antibodies, cetuximab and panitumumab, because those drugs only work when the RAS pathway downstream is intact. A 2026 study of 37 patients with RAS wild type metastatic colorectal cancer looked at whether staying on anti-EGFR treatment as maintenance was better than stopping and watching. The patients who stayed on it did go longer before their disease grew, though the difference between the two groups did not reach statistical significance, and the authors were blunt that the study was small, retrospective, and vulnerable to selection bias.

That’s colorectal cancer. Patients hear “RAS wild type” from a colon cancer forum or a general oncology page and reasonably assume the same door opens for them.

In appendiceal adenocarcinoma, it mostly hasn’t. A Memorial Sloan Kettering review of 1,505 appendiceal adenocarcinoma patients, with Dr. Mike Foote as senior author, found that among the 47 who received MAPK-targeted drugs, EGFR inhibitors showed limited efficacy, and the result held irrespective of the patient’s KRAS status. Wild type did not rescue those drugs. Dr. Foote serves on Appendicure’s board of directors and medical advisory board, and I’ve written that study up in more detail in Appendix Cancer Targeted Therapy.

The researchers who found no KRAS or NRAS mutations in goblet cell tumors noted in their paper that this absence might make some of those tumors eligible for anti-EGFR therapy. That was a hypothesis raised by a 25-case sequencing study. It has never been tested in an appendiceal trial. If someone quotes it to you as evidence that anti-EGFR drugs work in goblet cell disease, they are quoting a suggestion, not a result.

Wild type is not good news or bad news

People want the report to mean something about their odds. I understand the pull. But wild type is a description of a test, not a forecast. Researchers are still working out which mutations track with which outcomes in appendiceal disease, the findings don’t line up neatly across studies, and none of it has been sorted out cleanly enough to hand a patient a prediction based on the absence of a mutation.

The subtype itself is still being argued over. The largest review of goblet cell adenocarcinoma to date, covering 1,225 cases from an English cancer registry, opens by noting that the varying names and classification systems used for this tumor have made published data hard to compare. If the field can’t agree on what to call it, nobody should be reading a fortune into a single line on your report.

What to ask if your report says wild type

These are reasonable questions to bring to your oncology team.

Ask which genes were on the panel and how many. Ask whether the test was run on your tissue or your blood, because they answer different questions. Ask which piece of tissue was used, the appendix primary or a peritoneal sample, and what percentage of it was tumor. Ask whether the testing included RNA or dedicated fusion analysis, because some structural alterations and gene fusions can be easier to detect with RNA-based testing than with DNA testing alone. Ask whether MSI, mismatch repair, and tumor mutational burden were reported. And ask whether there is enough tissue left in your block to send for a broader panel if the first one came up empty.

If you had surgery at one hospital and you’re treated at another, the block is usually still at the surgical hospital. Pathology departments do not keep tissue forever, and retention rules vary. I walked through how to make that call in Appendix Cancer Mutation Testing.

What this doesn’t cover

Dr. JP Shen, who ordered David’s testing, serves on Appendicure’s board of directors and medical advisory board. The two goblet cell sequencing studies described in detail here covered 25 and 34 tumors. Those are small numbers, and neither study was built to guide treatment. The pseudomyxoma findings apply to mucinous appendiceal disease and pseudomyxoma peritonei. The anti-EGFR maintenance data are colorectal, not appendiceal, and I’ve kept them labeled that way throughout.

The signet ring numbers come from cohorts of 17 and 27 patients, which is why I called it a hint. Well-differentiated neuroendocrine tumors of the appendix are not covered by any of this at all. Their molecular profile is a separate question with far less data behind it. Nothing here changes current management recommendations. The 2025 Peritoneal Surface Malignancies Consortium guidelines provide appendiceal-specific consensus guidance, while also acknowledging that some systemic treatment recommendations still rely on evidence extrapolated from colorectal cancer.

Common questions

What does wild type appendix cancer mean?

Wild type means the test did not detect a mutation in the gene or region being reported. It does not mean your entire tumor has no mutations. Wild type is a lab term for “unchanged,” and it describes the result of one test, not your whole tumor.

Does wild type mean I have no mutations?

No. A panel only reports on the genes it was built to test. In one small study, most goblet cell tumors tested on a 32-gene colorectal panel had no detectable mutations on that panel, while broader sequencing identified additional alterations.

Can a wild type result be wrong?

Yes. Mucinous appendiceal samples often contain very few tumor cells, which can dilute a mutation below the detection limit. In one study of 167 pseudomyxoma peritonei patients, retesting the original appendix tumor with sensitive methods found KRAS mutations in 89 percent and GNAS in 83 percent.

Does KRAS wild type mean I can take cetuximab or panitumumab?

Not automatically. That rule comes from metastatic colorectal cancer. In appendiceal adenocarcinoma, a review of 1,505 patients found EGFR inhibitors largely ineffective regardless of KRAS status. This is a conversation for your oncologist, not an assumption to make from a report.

Is “no actionable targets” the same as wild type?

No, and this trips up a lot of people. “No actionable targets” means nothing found in your tumor currently matches an approved drug or an open trial. The lab may still have found alterations, often listed further down the report as variants of unknown significance. That is a statement about today’s drug list, not about your tumor being empty.

Which appendix cancer subtypes come back wild type most often?

Goblet cell adenocarcinoma stands out for unusually low rates of the common KRAS and GNAS drivers, a pattern reported across multiple studies. Low-grade mucinous tumors and pseudomyxoma peritonei are the opposite, carrying KRAS, GNAS or both in roughly 90 percent or more of carefully handled samples. No study has published a direct comparison of how often each subtype comes back with nothing at all.

Is wild type good news or bad news?

Neither on its own. It is a description of a test result. Nobody should be giving you a prognosis based on the absence of a mutation in appendiceal disease.

Appendicure runs on donations from the community it serves. If this was useful to you, you can support the work here.

Sources

• Jesinghaus M, Konukiewitz B, Foersch S, et al. Appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-type adenocarcinoma of the appendix. Modern Pathology 2018;31:829-839. nature.com
• Johncilla M, Stachler M, Misdraji J, et al. Mutational landscape of goblet cell carcinoids and adenocarcinoma ex goblet cell carcinoids of the appendix is distinct from typical carcinoids and colorectal adenocarcinomas. Modern Pathology 2018;31:989-996. PubMed
• High prevalence of KRAS and GNAS mutations in pseudomyxoma peritonei underscores opportunities for targeted therapeutic strategies. Pleura and Peritoneum 2026. doi:10.1515/pp-2025-0034. Europe PMC
• Palmer K, Weerasuriya S, Chandrakumaran K, et al. Goblet cell adenocarcinoma of the appendix: a systematic review and incidence and survival of 1,225 cases from an English cancer registry. Frontiers in Oncology 2022;12:915028. PubMed
• Çokgezer S, et al. Effect of maintenance anti-EGFR therapy on survival in RAS wild-type metastatic colorectal cancer. Cerrahpaşa Medical Journal 2026. doi:10.5152/cjm.2026.26069. cerrahpasamedj.org
• Abdelfattah S, Vemula N, Gowda T, et al. Clinical benefit of MAPK inhibition in appendiceal adenocarcinoma. Cancer Research 2026;86(14_Suppl):Abstract A045.
• Ang CS-P, Shen JP, Hardy-Abeloos CJ, et al. Genomic landscape of appendiceal neoplasms. JCO Precision Oncology 2018;2:PO.17.00302. PubMed
• Foote MB, Walch H, Chatila W, et al. Molecular classification of appendiceal adenocarcinoma. Journal of Clinical Oncology 2023;41:1553-1564. PubMed
• Taniguchi SH, Takahashi M, Chiu SW, et al. Impact of genetic mutations on prognosis and chemotherapy efficacy in advanced appendiceal carcinoma. International Journal of Clinical Oncology 2025;30:914-925. PubMed
• Doll J, Maurus K, Köhler F, et al. Molecular profiling of low-grade appendiceal mucinous neoplasms (LAMN). Genes, Chromosomes and Cancer 2024;63(10):e23270. PubMed

This article is patient education, not medical advice. Bring your own report and these questions to your care team.